3 AI-Driven Medical Device Stocks to Watch in 2025

The medical device sector is rapidly integrating both generative and agentic AI to transform clinical workflows and patient care, enhancing diagnostics, imaging, and surgical robotics. This adoption is bolstered by a favorable regulatory environment, with over 700 FDA-approved AI-enabled devices. Key players like Boston Scientific (BSX), Johnson & Johnson (JNJ), and GE HealthCare (GEHC) are strategically leveraging AI; BSX, for instance, projects strong 2025 sales growth of 16.4% and earnings growth of 15.9% driven by its AI investments in cardiac diagnostics, while JNJ advances AI in surgical robotics and GEHC leads in FDA-cleared AI devices, positioning these firms for continued growth as AI reshapes the industry.

Analysis

The medical device sector is experiencing a significant transformation driven by the integration of generative and agentic AI, a trend supported by strong demand for precision medicine and a favorable regulatory environment. The U.S. FDA has notably approved over 700 AI-enabled devices, signaling reduced uncertainty and encouraging innovation. Within this landscape, Boston Scientific (BSX) emerges as a high-growth contender, leveraging AI in cardiac diagnostics and mapping systems. Its financial outlook is robust, with projected 2025 sales and earnings growth of 16.4% and 15.9% respectively, substantially outperforming a flat industry forecast, and supported by a strong current cash flow rate of 26.5%. Johnson & Johnson (JNJ) represents a stable, profitable incumbent, integrating AI into its next-generation surgical robotics and digital ecosystems. While its projected 2025 sales growth is a more modest 2.8%, its financial strength is evident in a 24.4% net margin, which surpasses the industry's 18.6%. GE HealthCare (GEHC) is positioned as a leader in regulatory adoption, holding the most FDA-cleared AI devices with 80 authorizations. While its projected 2025 sales growth of 3.2% and current cash flow rate of 9.7% are solid, its Zacks Rank #3 (Hold) suggests a more neutral outlook compared to the 'Buy' ratings for BSX and JNJ.

Key Decisions for Investors

• Investors seeking aggressive growth within the MedTech AI theme should evaluate Boston Scientific, given its superior projected sales and earnings growth of 16.4% and 15.9% for 2025.
• For those prioritizing profitability and a more diversified exposure, Johnson & Johnson offers a compelling case with its industry-leading 24.4% net margin and strategic advancements in the high-value surgical robotics market.
• While GE HealthCare leads in the quantity of FDA-cleared AI devices, its more moderate growth forecast and 'Hold' rating suggest a cautious approach, potentially as a stable holding rather than a primary growth vehicle in the space.
• Monitor the commercial traction of newly launched AI products and the continued pace of FDA approvals, as these are critical catalysts that will validate the investment thesis for these companies.